Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Biotechnology Industry — Last 30 Days

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume
Sep 15, 2026
Sale
Shares
100
Price
$15.88
Total Value
$1.59K
Shares Held After
6,351
% of Holdings
1.6%
Sep 15, 2026
Sale
Shares
18,321
Price
$15.09
Total Value
$276.46K
Shares Held After
6,451
% of Holdings
74.0%
Sep 15, 2026
Sale
Shares
18,500
Price
$37.00
Total Value
$684.50K
Shares Held After
235,244
% of Holdings
7.3%
Sep 15, 2026
Sale
Shares
1,000
Price
$72.98
Total Value
$72.98K
Shares Held After
0
% of Holdings
100.0%

Travere Therapeutics, Inc. (TVTX)

Inrig Jula — EVP, Head of R&D&CMO
Sep 15, 2026
Sale
Shares
400
Price
$65.31
Total Value
$26.12K
Shares Held After
100,491
% of Holdings
0.4%

Travere Therapeutics, Inc. (TVTX)

Inrig Jula — EVP, Head of R&D&CMO
Sep 15, 2026
Sale
Shares
1,600
Price
$63.69
Total Value
$101.90K
Shares Held After
100,891
% of Holdings
1.6%

Travere Therapeutics, Inc. (TVTX)

Inrig Jula — EVP, Head of R&D&CMO
Sep 15, 2026
Sale
Shares
17,284
Price
$62.62
Total Value
$1.08M
Shares Held After
102,491
% of Holdings
14.4%

Travere Therapeutics, Inc. (TVTX)

Inrig Jula — EVP, Head of R&D&CMO
Sep 15, 2026
Sale
Shares
25,390
Price
$62.02
Total Value
$1.57M
Shares Held After
119,775
% of Holdings
17.5%

Travere Therapeutics, Inc. (TVTX)

Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026
Sale
Shares
300
Price
$63.66
Total Value
$19.10K
Shares Held After
42,353
% of Holdings
0.7%

Travere Therapeutics, Inc. (TVTX)

Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026
Sale
Shares
800
Price
$62.85
Total Value
$50.28K
Shares Held After
42,653
% of Holdings
1.8%

Travere Therapeutics, Inc. (TVTX)

Calvin Sandra — SVP, CHIEF ACCOUNTING OFFICER
Sep 15, 2026
Sale
Shares
4,275
Price
$62.13
Total Value
$265.63K
Shares Held After
43,453
% of Holdings
9.0%

Travere Therapeutics, Inc. (TVTX)

Cline Christopher R. — CHIEF FINANCIAL OFFICER
Sep 15, 2026
Sale
Shares
400
Price
$65.31
Total Value
$26.12K
Shares Held After
87,508
% of Holdings
0.5%

Travere Therapeutics, Inc. (TVTX)

Cline Christopher R. — CHIEF FINANCIAL OFFICER
Sep 15, 2026
Sale
Shares
1,900
Price
$63.69
Total Value
$121.00K
Shares Held After
87,908
% of Holdings
2.1%

Travere Therapeutics, Inc. (TVTX)

REED ELIZABETH E — Chief Legal Officer and GC
Sep 15, 2026
Sale
Shares
300
Price
$65.31
Total Value
$19.59K
Shares Held After
105,389
% of Holdings
0.3%
Sep 15, 2026
Sale
Shares
270
Price
$65.31
Total Value
$17.63K
Shares Held After
432,886
% of Holdings
0.1%

Travere Therapeutics, Inc. (TVTX)

Cline Christopher R. — CHIEF FINANCIAL OFFICER
Sep 15, 2026
Sale
Shares
20,735
Price
$62.61
Total Value
$1.30M
Shares Held After
89,808
% of Holdings
18.8%
Sep 15, 2026
Sale
Shares
3,102
Price
$63.64
Total Value
$197.42K
Shares Held After
433,156
% of Holdings
0.7%

Travere Therapeutics, Inc. (TVTX)

REED ELIZABETH E — Chief Legal Officer and GC
Sep 15, 2026
Sale
Shares
1,400
Price
$63.69
Total Value
$89.17K
Shares Held After
105,689
% of Holdings
1.3%
Sep 15, 2026
Sale
Shares
28,796
Price
$62.66
Total Value
$1.80M
Shares Held After
436,258
% of Holdings
6.2%

Travere Therapeutics, Inc. (TVTX)

Cline Christopher R. — CHIEF FINANCIAL OFFICER
Sep 15, 2026
Sale
Shares
27,473
Price
$62.00
Total Value
$1.70M
Shares Held After
110,543
% of Holdings
19.9%

Travere Therapeutics, Inc. (TVTX)

REED ELIZABETH E — Chief Legal Officer and GC
Sep 15, 2026
Sale
Shares
13,874
Price
$62.63
Total Value
$868.96K
Shares Held After
107,089
% of Holdings
11.5%
Sep 15, 2026
Sale
Shares
63,498
Price
$61.99
Total Value
$3.94M
Shares Held After
465,054
% of Holdings
12.0%

Travere Therapeutics, Inc. (TVTX)

REED ELIZABETH E — Chief Legal Officer and GC
Sep 15, 2026
Sale
Shares
21,926
Price
$62.03
Total Value
$1.36M
Shares Held After
120,963
% of Holdings
15.3%

Travere Therapeutics, Inc. (TVTX)

ROTE WILLIAM E. — Chief Research Officer
Sep 15, 2026
Sale
Shares
270
Price
$65.31
Total Value
$17.63K
Shares Held After
98,197
% of Holdings
0.3%

Travere Therapeutics, Inc. (TVTX)

ROTE WILLIAM E. — Chief Research Officer
Sep 15, 2026
Sale
Shares
3,000
Price
$63.65
Total Value
$190.95K
Shares Held After
98,467
% of Holdings
3.0%

Travere Therapeutics, Inc. (TVTX)

ROTE WILLIAM E. — Chief Research Officer
Sep 15, 2026
Sale
Shares
29,021
Price
$62.66
Total Value
$1.82M
Shares Held After
101,467
% of Holdings
22.2%

Travere Therapeutics, Inc. (TVTX)

ROTE WILLIAM E. — Chief Research Officer
Sep 15, 2026
Sale
Shares
63,907
Price
$61.99
Total Value
$3.96M
Shares Held After
130,488
% of Holdings
32.9%

Travere Therapeutics, Inc. (TVTX)

Heerma Peter — EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026
Sale
Shares
1,431
Price
$65.31
Total Value
$93.46K
Shares Held After
117,066
% of Holdings
1.2%

Travere Therapeutics, Inc. (TVTX)

Heerma Peter — EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026
Sale
Shares
1,400
Price
$63.65
Total Value
$89.11K
Shares Held After
118,497
% of Holdings
1.2%

Travere Therapeutics, Inc. (TVTX)

Heerma Peter — EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026
Sale
Shares
27,421
Price
$62.59
Total Value
$1.72M
Shares Held After
119,897
% of Holdings
18.6%

Travere Therapeutics, Inc. (TVTX)

Heerma Peter — EVP, CHIEF COMMERCIAL OFFICER
Sep 15, 2026
Sale
Shares
71,938
Price
$62.05
Total Value
$4.46M
Shares Held After
147,318
% of Holdings
32.8%
Sep 15, 2026
Sale
Shares
400
Price
$40.45
Total Value
$16.18K
Shares Held After
36,108
% of Holdings
1.1%
Sep 15, 2026
Sale
Shares
600
Price
$40.38
Total Value
$24.23K
Shares Held After
9,900
% of Holdings
5.7%
Sep 15, 2026
Sale
Shares
4,712
Price
$39.68
Total Value
$186.97K
Shares Held After
36,508
% of Holdings
11.4%
Sep 15, 2026
Sale
Shares
4,338
Price
$39.65
Total Value
$172.00K
Shares Held After
10,500
% of Holdings
29.2%

Adaptive Biotechnologies Corp (ADPT)

BOBULSKY SUSAN — Chief Commercial Officer, MRD
Sep 15, 2026
Sale
Shares
1,195
Price
$27.00
Total Value
$32.27K
Shares Held After
395,794
% of Holdings
0.3%
Sep 15, 2026
Sale
Shares
3,000
Price
$28.58
Total Value
$85.74K
Shares Held After
6,200
% of Holdings
32.6%

Theravance Biopharma, Inc. (TBPH)

Farnum Rhonda — SVP, COMM&MEDICAL AFFAIRS
Sep 15, 2026
Sale
Shares
6,657
Price
$17.03
Total Value
$113.40K
Shares Held After
213,476
% of Holdings
3.0%

Theravance Biopharma, Inc. (TBPH)

Farnum Rhonda — SVP, COMM&MEDICAL AFFAIRS
Sep 15, 2026
Sale
Shares
3,328
Price
$17.03
Total Value
$56.69K
Shares Held After
220,133
% of Holdings
1.5%

Theravance Biopharma, Inc. (TBPH)

Farnum Rhonda — SVP, COMM&MEDICAL AFFAIRS
Sep 15, 2026
Sale
Shares
3,329
Price
$17.03
Total Value
$56.71K
Shares Held After
223,461
% of Holdings
1.5%
Sep 15, 2026
Sale
Shares
66
Price
$80.01
Total Value
$5.28K
Shares Held After
94,487
% of Holdings
0.1%
Sep 15, 2026
Sale
Shares
759
Price
$79.00
Total Value
$59.96K
Shares Held After
94,553
% of Holdings
0.8%
Sep 15, 2026
Sale
Shares
11,675
Price
$78.33
Total Value
$914.50K
Shares Held After
95,312
% of Holdings
10.9%
Sep 15, 2026
Sale
Shares
100,000
Price
$13.67
Total Value
$1.37M
Shares Held After
467,969
% of Holdings
17.6%

INCYTE CORP (INCY)

CAGNONI PABLO J — President, Global Head of R&D
Sep 15, 2026
Sale
Shares
13,985
Price
$120.49
Total Value
$1.69M
Shares Held After
183,200
% of Holdings
7.1%

INCYTE CORP (INCY)

CAGNONI PABLO J — President, Global Head of R&D
Sep 15, 2026
Sale
Shares
9,233
Price
$120.50
Total Value
$1.11M
Shares Held After
197,185
% of Holdings
4.5%
Sep 15, 2026
Sale
Shares
4,730
Price
$24.18
Total Value
$114.37K
Shares Held After
35,841
% of Holdings
11.7%

Pharvaris N.V. (PHVS)

Abele Stefan Andreas — Chief Technical Ops Officer
Sep 15, 2026
Sale
Shares
1,400
Price
$39.24
Total Value
$54.94K
Shares Held After
39,068
% of Holdings
3.5%

Pharvaris N.V. (PHVS)

Abele Stefan Andreas — Chief Technical Ops Officer
Sep 15, 2026
Sale
Shares
45,000
Price
$38.14
Total Value
$1.72M
Shares Held After
40,468
% of Holdings
52.7%

Pharvaris N.V. (PHVS)

Glassman Robert — Director
Sep 15, 2026
Sale
Shares
8,667
Price
$38.27
Total Value
$331.72K
Shares Held After
10,500
% of Holdings
45.2%
Version: v26.9.1